Nectar Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 27 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.25 Cr
- Revenue Growth -23.77%
- Profit Growth -70.39%
- Ebitda 235.32%
- Net Worth 1.24%
- Total Assets -35.10%
About Nectar Drugs
Nectar Drugs Private Limited (NDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 05 November 1997 and has a history of 27 years and three months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹1.25 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rajesh Badani and Deven Badani serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230MH1997PTC111699
- Company No.
111699
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Nov 1997
- Date of AGM
07 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Nectar Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Badani  | Director | 05-Nov-1997 | Current |
| Deven Badani | Director | 05-Nov-1997 | Current |
Financial Performance of Nectar Drugs.
Nectar Drugs Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 23.77% decrease. The company also saw a substantial fall in profitability, with a 70.39% decrease in profit. The company's net worth moved up by a moderate rise of 1.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nectar Drugs?
In 2021, Nectar Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹12.50 M
Charges Breakdown by Lending Institutions
- The Lakshmi Vilas Bank Limited : 1.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Mar 2001 | The Lakshmi Vilas Bank Limited | ₹1.25 Cr | Satisfied |
How Many Employees Work at Nectar Drugs?
Unlock and access historical data on people associated with Nectar Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nectar Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nectar Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
